Monte Rosa Therapeutics - Presentations

12.11.2024 Presentations

San Antonio Breast Cancer Symposium – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer

10.30.2024 Presentations

7th Annual TPD & Induced Proximity Summit – Molecular Glue Degraders: From the Bench to the Clinic

10.29.2024 Presentations

7th Annual TPD & Induced Proximity Summit – Rational Design of Selective CDK2 and Cyclin E1 MGDs

10.23.2024 Presentations

Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies

9.11.2024 Presentations

6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader

7.26.2024 Presentations

Trends in Immunology – VAV1 as a Putative Therapeutic Target in Autoimmune and Chronic Inflammatory Diseases

6.14.2024 Presentations

EULAR 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model

5.21.2024 Presentations

DDW 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression

4.8.2024 Presentations

AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer

1.31.2024 Presentations

Molecular Glue Drug Development Summit January 2024 – Accelerating Molecular Glue Discovery Through AI/ML & Computation

1.25.2024 Presentations

Keystone Symposia January 2024 – Teaching CRBN New Tricks

11.16.2023 Presentations

ACR 2023 – A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model

10.17.2023 Presentations

Monte Rosa Company Call Presentation – October 17 2023

4.17.2023 Presentations

AACR 2023 – Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers

4.17.2023 Presentations

AACR 2023 – Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction

10.25.2022 Presentations

MRT-2359 KOL Webinar, October 24, 2022

10.24.2022 Presentations

34th EORTC-NCI-AACR Symposium

10.23.2022 Presentations

5th Annual TPD Summit – Preclinical and Mechanism of Action Studies of MRT-2359

10.22.2022 Presentations

5th Annual TPD Summit – AI Applications for Molecular Glue Degraders

3.29.2022 Presentations

American Association for Cancer Research Annual Meeting, April 8-13, 2022

3.1.2022 Presentations

2nd Annual TPD Europe Summit Presentation

10.27.2021 Presentations

4th Annual Targeted Protein Degradation Summit Presentation

10.6.2021 Presentations

AACR-NCI-EORTC Late Breaking Presentation

9.7.2021 Presentations

European Protein Degradation Congress 2021 Presentation